Polylactic‐ Glycolic Acid Microparticles–Encapsulated Prostaglandin E1 as A Novel Strategy In Triple Negative Breast Cancer

Triple-negative breast cancer (TNBC) is characterized by unique clinical and pathological traits, from which its aggressive nature and the absence of specific treatments are the most worrying. Prostaglandin E₁ (PGE₁) can affect the morphology of human breast tumor cell lines, but its potential therapeutic effects appear to be counteracted by its high degradability in physiological environments. For this reason, polylactic-glycolic acid polymeric microparticles (MPs) are developed to stabilize PGE₁ in damp conditions and enable sustained local release for the treatment of TNBC after surgical removal of the tumor mass. Specifically, the PGE₁ embedded MPs are produced using a double emulsion solvent-evaporation method, then analyzed through Mastersizer and scanning electron microscopy. Afterward, the encapsulation efficiency and the PGE₁ release are examined using liquid chromatography-mass spectrometry, and their stability at various storage temperatures is assessed. Finally, the carrier toxicity is evaluated in TNBC cells and colon adenocarcinoma epithelial cells, Caco-2. A reliable action on carcinogenic cells specific to breast cancer is observed. Although in vivo studies are still needed, these results open the way to using such a carrier for the intralesional delivery of PGE₁ and its use against TNBC.